Yuan-Tong Liu

Oncology · 2021

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Yuan-Tong Liu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Daniel S. Chen
  2. P. Hegde

Who trusts Yuan-Tong Liu overall

  1. Shreelaxmi Gavas

Papers from Yuan-Tong Liu's perspective

Ordered by how strongly the researchers Yuan-Tong Liu trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
  2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  3. Hallmarks of cancer: the next generation. (Cell)
  4. Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients (New England Journal of Medicine)
  5. Calreticulin exposure dictates the immunogenicity of cancer cell death (Nature Medicine)
  6. Immunogenic cell death in cancer therapy. (Annual Review of Immunology)
  7. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
  8. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  9. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  10. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (Nature Medicine)

Their papers